The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease
出版年份 2012 全文链接
标题
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease
作者
关键词
-
出版物
PLoS One
Volume 7, Issue 7, Pages e40776
出版商
Public Library of Science (PLoS)
发表日期
2012-07-19
DOI
10.1371/journal.pone.0040776
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
- (2012) Elfrida R Benjamin et al. MOLECULAR THERAPY
- Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders
- (2011) Kenneth J. Valenzano et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease
- (2011) Caterina Porto et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers
- (2011) Mathews Adera et al. MOLECULAR GENETICS AND METABOLISM
- Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle
- (2011) Dwight D. Koeberl et al. MOLECULAR GENETICS AND METABOLISM
- Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype
- (2010) N. P. van Til et al. BLOOD
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
- (2010) A. Joseph et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease
- (2010) Chyan-Jang Lee et al. Journal of Cardiology
- High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
- (2010) Juna M. de Vries et al. MOLECULAR GENETICS AND METABOLISM
- A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
- (2010) Ans T. van der Ploeg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immortalization of murine muscle cells from lysosomal α-glucosidase deficient mice: A new tool to study pathophysiology and assess therapeutic strategies for Pompe disease
- (2009) Gaëlle Douillard-Guilloux et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
- (2009) Marc Nicolino et al. GENETICS IN MEDICINE
- The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase
- (2009) John J. Flanagan et al. HUMAN MUTATION
- Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
- (2009) S. Strothotte et al. JOURNAL OF NEUROLOGY
- Temporal Neuropathologic and Behavioral Phenotype of 6neo/6neoPompe Disease Mice
- (2009) Richard L. Sidman et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Reversal of Cardiac Dysfunction after Enzyme Replacement in Patients with Infantile-Onset Pompe Disease
- (2009) Lei-Ru Chen et al. JOURNAL OF PEDIATRICS
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
- (2009) Priya S. Kishnani et al. MOLECULAR GENETICS AND METABOLISM
- The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
- (2009) Caterina Porto et al. MOLECULAR THERAPY
- Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease
- (2009) Yunxiang Zhu et al. MOLECULAR THERAPY
- Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease
- (2009) Baodong Sun et al. MOLECULAR THERAPY
- G.P.8.05 The pharmacological chaperone AT2220 increases mutant acid alpha-glucosidase levels and reduces tissue glycogen in a mouse model of Pompe disease
- (2009) R. Khanna et al. NEUROMUSCULAR DISORDERS
- Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
- (2009) Nancy J. Mendelsohn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neural deficits contribute to respiratory insufficiency in Pompe disease
- (2009) L. R. DeRuisseau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase
- (2008) Jin-Song Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pompe's disease
- (2008) Ans T van der Ploeg et al. LANCET
- Therapeutic approaches in glycogen storage disease type II/pompe disease
- (2008) Benedikt Schoser et al. Neurotherapeutics
- A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity
- (2007) Jian-Qiang Fan BIOLOGICAL CHEMISTRY
- Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease
- (2007) Maarten R. Drost et al. MUSCLE & NERVE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started